Bridgebio Stock Performance


USD 9.24  0.16  1.76%   

The firm shows a Beta (market volatility) of 2.4691, which signifies a somewhat significant risk relative to the market. Let's try to break down what Bridgebio's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bridgebio Pharma will likely underperform. Although it is important to respect Bridgebio Pharma historical returns, it is better to be realistic regarding the information on the equity's current trending patterns. The philosophy towards foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Bridgebio Pharma technical indicators, you can presently evaluate if the expected return of 0.0623% will be sustainable into the future. Bridgebio Pharma right now shows a risk of 7.2%. Please confirm Bridgebio Pharma variance, as well as the relationship between the maximum drawdown and semi variance to decide if Bridgebio Pharma will be following its price patterns.
Bridgebio Performance
0 of 100
Over the last 90 days Bridgebio Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent forward indicators, Bridgebio Pharma is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more

Bridgebio Price Channel

Quick Ratio6.34
Fifty Two Week Low4.98
Target High Price32.00
Fifty Two Week High65.33
Target Low Price17.00

Bridgebio Pharma Relative Risk vs. Return Landscape

If you would invest  1,043  in Bridgebio Pharma on March 28, 2022 and sell it today you would lose (119.00)  from holding Bridgebio Pharma or give up 11.41% of portfolio value over 90 days. Bridgebio Pharma is currently generating 0.0623% in daily expected returns and assumes 7.1979% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Bridgebio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Bridgebio Pharma is expected to generate 5.01 times more return on investment than the market. However, the company is 5.01 times more volatile than its market benchmark. It trades about 0.01 of its potential returns per unit of risk. The DOW is currently generating roughly -0.11 per unit of risk.

Bridgebio Pharma Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Bridgebio Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bridgebio Pharma, and traders can use it to determine the average amount a Bridgebio Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0087

Good Returns
Average Returns
Small Returns
Negative Returns
Estimated Market Risk
  actual daily
 62 %
of total potential
Expected Return
  actual daily
 1 %
of total potential
Risk-Adjusted Return
  actual daily
 0 %
of total potential
Based on monthly moving average Bridgebio Pharma is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bridgebio Pharma by adding it to a well-diversified portfolio.

About Bridgebio Pharma Performance

To evaluate Bridgebio Pharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Bridgebio Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Bridgebio Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Bridgebio Pharma stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Bridgebio's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Average Assets(0.57) (0.61) 
Return on Average Equity 0.91  0.98 
Return on Invested Capital(0.26) (0.28) 
Return on Sales(7.40) (7.98) 
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 576 people.

Things to note about Bridgebio Pharma

Checking the ongoing alerts about Bridgebio Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Bridgebio Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Bridgebio Pharma Alerts

Equity Alerts and Improvement Suggestions

Bridgebio Pharma has very high historical volatility over the last 90 days
Bridgebio Pharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 69.72 M. Net Loss for the year was (562.54 M) with profit before overhead, payroll, taxes, and interest of 66.6 M.
Bridgebio Pharma currently holds about 836.66 M in cash with (497.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67.
Bridgebio Pharma has a poor financial position based on the latest SEC disclosures
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Acquisition by Ellis Andrea of 104921 shares of Bridgebio Pharma subject to Rule 16b-3
Continue to Trending Equities. Note that the Bridgebio Pharma information on this page should be used as a complementary analysis to other Bridgebio Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Bridgebio Stock analysis

When running Bridgebio Pharma price analysis, check to measure Bridgebio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridgebio Pharma is operating at the current time. Most of Bridgebio Pharma's value examination focuses on studying past and present price action to predict the probability of Bridgebio Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bridgebio Pharma's price. Additionally, you may evaluate how the addition of Bridgebio Pharma to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Is Bridgebio Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bridgebio Pharma. If investors know Bridgebio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bridgebio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.4 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Bridgebio Pharma is measured differently than its book value, which is the value of Bridgebio that is recorded on the company's balance sheet. Investors also form their own opinion of Bridgebio Pharma's value that differs from its market value or its book value, called intrinsic value, which is Bridgebio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bridgebio Pharma's market value can be influenced by many factors that don't directly affect Bridgebio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bridgebio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Bridgebio Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bridgebio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.